Clinical Trials

65 enrolled

Biliary Tract Neoplasms

NCT05532319 2025-12-30

FRONT-1

64 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT06494189 2025-12-29

Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous Carcinoma

9 enrolled

Head & Neck

Head and Neck Neoplasms

NCT05622071 2025-11-17

HESTIA

50 enrolled

Carcinoma, Hepatocellular

NCT04047186 2025-09-23

Neoadjuvant Immunotherapy in Early Stage Non-small-cell Lung Cancer Presenting as Synchronous Ground-glass Nodules

12 enrolled

Lung Neoplasms, Multiple Pulmonary Nodules

NCT05880082 2025-08-24

PPIO-004-EC001

118 enrolled

Esophageal Squamous Cell Carcinoma

NCT07098104 2025-08-01

A Benefit Population Atlas of nICT Versus nCT for LAGC

Completed

291 enrolled

Stomach Neoplasms

NCT05517330 2025-07-31

neoCHANCE-1

23 enrolled

Head & Neck

Head and Neck Neoplasms

NCT04963088 2025-06-26

TALENT

Phase 1/2 Completed

65 enrolled

Stomach Neoplasms

NCT05044871 2025-06-08

BRIGHT

108 enrolled

Gynecologic

Ovarian Neoplasms

NCT05516589 2025-05-22

neoCHANCE-2

40 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05542342 2025-05-14

SITISVEAL

16 enrolled

Dermatologic

Uveal Melanoma

NCT05058560 2025-03-13

Tislelizumab in Addition to BACE in Patients with NSCLC

30 enrolled

NSCLC

NCT05303090 2025-02-27

Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients With Advanced Pancreatic Cancer

56 enrolled

Pancreatic Ductal Adenocarcinoma

NCT05086627 2024-08-22

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

118 enrolled

Locally Advanced Rectal Cancer

NCT06232759 2024-06-10

TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma

56 enrolled

Carcinoma, Hepatocellular

NCT04310943 2024-03-06

Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma

24 enrolled

Adenocarcinoma of Lung

NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Completed

600 enrolled

Carcinoma, Hepatocellular, Liver Diseases

NCT06238752 2024-02-02

RENMIN-213

33 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT06022692 2023-09-05

HEAIS001

Phase 1/2 Completed

18 enrolled

Hyperthermia, Digestive System Neoplasms

NCT04507217 2023-05-25

Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC

36 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT05809336 2023-04-12

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Phase 2/3 Completed

172 enrolled

Other solid neoplasm

Advanced Solid Tumor

NCT03732664 2023-03-24

ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer

27 enrolled

High-Risk Resectable NSCLC

NCT03287427 2023-02-15

MYPHISMO

27 enrolled